In this Peer Exchange, a panel of specialists examine the current and developing treatment options for age-related macular degeneration, with a focus on faricimab.
EP. 1: Defining Age-Related Macular Degeneration
Nancy L. Holekamp, MD, defines age-related macular degeneration (AMD), while Jennifer I. Lim, MD, discusses signs and symptoms that are usually present in patients before diagnosis.
EP. 2: Age-Related Macular Degeneration Diagnosis
Carl Regillo, MD, FACS, discusses diagnosing patient with age-related macular degeneration.
EP. 3: Specialist Referrals and Therapy Goals for Patients With AMD
Lloyd Clark, MD, provides examples of when clinicians should refer patients with AMD to specialists, and Carl Regillo, MD, FACS, explains the typical therapy goals a specialist has for each patient.
EP. 4: Anti-VEGF Agent Therapy Considerations for Patients With AMD
Lloyd Clark, MD, and Jennifer I. Lim, MD, give their insight into therapy considerations when deciding to use anti-VEGF agents to treat age-related macular degeneration.
EP. 5: Anti-VEGF Agent Safety
Nancy M. Holekamp, MD, and Carl Regillo, MD, FACS, discuss the safety aspects of anti-VEGF agents when treating age-related macular degeneration.
EP. 6: Additional Diagnostic Tools for Anti-VEGF Agents and Using Brolucizumab
Dr Clark details additional diagnostic tools he uses when deciding to use anti-VEGF agents, as well as his experience using the drug brolucizumab, and Dr Regillo elaborates on brolucizumab.
EP. 7: Faricimab and TENAYA and LUCERNE Trials
Drs Lim, Holekamp, and Regillo discuss the introduction of the drug faricimab as a therapy option for age-related macular degeneration and the data from the TEYANA and LUCERNE clinical trials.
EP. 8: YOSEMITE and RHINE Trials for Patients With Diabetes and AMD
Two specialists examine the YOSEMITE and RHINE clinical trials that explored faricimab as a therapeutic option for patients with both diabetes and age-related macular degeneration.
EP. 9: VEGF Inhibitors With Potential to Treat AMD: Port Delivery System
Two specialists give their insight into a VEGF inhibitor that could potentially be used as an effective treatment for age-related macular degeneration: port delivery system.
EP. 10: VEGF Inhibitors With Potential to Treat AMD: KSI-301
Lloyd Clark, MD, discusses a different VEGF inhibitor that could have a positive effect on age-related macular degeneration treatment: KSI-301.
EP. 11: Unmet Needs for Patients With AMD
The panel closes out this Peer Exchange by relaying their idea of unmet needs found when using the available treatment options for age-related macular degeneration.
2 Clarke Drive Cranbury, NJ 08512